Table 2.
Clinical outcomes during follow-up periods between patients with and without AOI
| Variables | AOI positive (n = 98) |
AOI negative (n = 278) |
p value |
|---|---|---|---|
| Maximal extent, no. (%) | 0.699 | ||
| Proctitis, no. (%) | 39 (39.8) | 115 (41.4) | |
| Left-sided colitis, no. (%) | 29 (29.6) | 84 (30.2) | |
| Extensive colitis, no. (%) | 30 (30.6) | 79 (28.4) | |
| Proximal extension, no. (%) | 24 (24.5) | 50 (18.0) | 0.184 |
| Mayo endoscopic score at the last endoscopy | 0.516 | ||
| 0–1, no. (%) | 73 (74.5) | 196 (70.5) | |
| 2–3, no. (%) | 25 (25.5) | 82 (29.5) | |
| Histories of medications | |||
| High dose 5-ASA, no (%) | 13 (13.3) | 69 (24.8) | 0.016 |
| Corticosteroid, no. (%) | 53 (54.1) | 150 (54.0) | 1.000 |
| Azathioprine/6-MP, no. (%) | 27 (27.6) | 86 (30.9) | 0.609 |
| Anti-TNF agents, no. (%) | 2 (2.0) | 17 (6.1) | 0.177 |
| Colectomy, no. (%) | 0 (0.0) | 2 (0.7) | 1.000 |
| UC-related hospitalization, no. (%) | 25 (25.5) | 75 (27.0) | 0.894 |
| Relapse during follow-up periods, no. (%) | 44 (44.9) | 108 (38.8) | 0.338 |
| Follow-up duration, months, median (range) | 56.5 (1-186) | 52.0 (1-245) | 0.285 |
P value < 0.05 was regarded as statistically significant and is designated in bold
AOI appendiceal orifice inflammation, 5-ASA 5-aminosalicylic acid, MP mercaptopurine, TNF tumor necrosis factor, UC ulcerative colitis, SD standard deviation